...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature clinical practice:Urology >Incorporating fluorescence cystoscopy for the diagnosis of bladder cancer into clinical practice.
【24h】

Incorporating fluorescence cystoscopy for the diagnosis of bladder cancer into clinical practice.

机译：将荧光膀胱镜用于诊断膀胱癌纳入临床实践。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the Western World, transitional cell carcinoma (TCC) of the bladder represents the fourth most frequently diagnosed malignancy, and in 2008 an estimated 68,810 new incidences of TCC of the bladder will be diagnosed in the US. Of the patients newly diagnosed with bladder cancer, approximately 80% present with a non-muscle-invasive tumor. A wide range of recurrence and progression rates exists in patients with bladder cancer, and these rates depend largely on the number of tumors initially identified, tumor size, prior recurrence rate, T category, tumor grade and concomitant carcinoma in situ (CIS). According to data from the European Organisation for Research and Treatment of Cancer (EORTC), the probability of recurrence at 5 years after diagnosis is 31-78%, and the probability of disease progression at 5 years is <1%-45%. These high recurrence and progression rates have resulted in long-term surveillance and therapy for patients with bladder cancer, making TCC of the bladder the fifth most expensivecancer in terms of total medical care expenditures (almost dollar 3.7 billion in 2001 in the US).
机译：在西方世界，膀胱移行细胞癌（TCC）代表第四大最常被诊断为恶性肿瘤，2008年，在美国估计将诊断出68,810例新的膀胱TCC发病率。在新近被诊断出患有膀胱癌的患者中，大约80％患有非肌肉浸润性肿瘤。膀胱癌患者存在广泛的复发和进展率，这些率在很大程度上取决于最初鉴定出的肿瘤数量，肿瘤大小，先前的复发率，T类别，肿瘤等级和原位癌（CIS）。根据欧洲癌症研究与治疗组织（EORTC）的数据，诊断后5年复发的概率为31-78％，而5年疾病进展的概率为<1％-45％。这些高的复发率和进展率导致了对膀胱癌患者的长期监视和治疗，使膀胱癌在总医疗保健支出中名列第五（在美国，2001年将近37亿美元）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号